Combination therapy

3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer.

A new treatment for some people with a type of non small cell lung cancer (NSCLC) will now be routinely available on the NHS in England, following its approval by the National Institute of Health and Care Excellence (NICE).

People who have previously been treated for a type of bowel cancer that has spread to other parts of their body will now have another treatment option in England.

A potentially life-extending treatment for some people with non small cell lung cancer (NSCLC) will now be available on the NHS in England.

The three latest SMC decisions will provide new treatment options for some adults with non small cell lung cancer, multiple myeloma and a rare type of lymphoma.

Following its approval in Scotland 2 weeks ago, a new treatment will now be available on the NHS in England for some people with prostate cancer.

The Scottish Medicines Consortium (SMC) has approved 4 new cancer drugs for use on the NHS in Scotland to treat some lung, breast and prostate cancers.

A drug combination for people with a rare type of bowel cancer has received an initial rejection from the National Institute for Health and Care Excellence.

The National Institute for Health and Care Excellence has recommended a new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma.

The National Institute for Health and Care Excellence (NICE) has approved the drug brentuximab vedotin on the NHS in England.